IP Library Granted Patent US 10,981,889
Granted Patent B2
US 10,981,889 · App. 16/780,155 · Granted Apr 20, 2021

4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

Inventors: John Andrew Christopher (Cambridge, GB); Miles Stuart Congreve (Cambridge, GB); Sarah Joanne Aves (Cambridge, GB); Benjamin Gerald Tehan (Cambridge, GB)
Assignee: Heptares Therapeutics Limited
C07D401/04C07D239/26C07D403/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,981,889
App. No.
16/780,155
Granted
Apr 20, 2021
Kind
B2
Abstract

The disclosures herein relate to novel compounds of formula wherein R 1 , R 2 , R 3 and R 4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

Claims (66)

1. A compound of formula 2:

or a salt thereof, wherein

R 1 is halogen, optionally substituted C 1 -C 3 alkyl, cyclopropyl, optionally substituted C 1 -C 3 alkoxy, cyano, hydroxyl, nitro or NH 2 ;

R 2 is H or F; and

Q is an optionally substituted pyridyl or pyrazyl group.

2. The compound according to claim 1 which is a compound of formula 3:

or a salt thereof, wherein

R 1 is halogen, optionally substituted C 1 -C 3 alkyl, cyclopropyl, optionally substituted C 1 -C 3 alkoxy, cyano, hydroxyl, nitro or NH 2 ;

R 2 is H or F;

R 3 is H, halogen, optionally substituted C 1 -C 3 alkyl, optionally substituted C 1 -C 3 alkoxy or cyano; and

R 4 is H, halogen, optionally substituted C 1 -C 3 alkyl, optionally substituted C 1 -C 3 alkoxy or cyano; and

n is 0-3.

3. The compound according to claim 1 which is a compound of formula 4:

or a salt thereof, wherein

R 1 is halogen, optionally substituted C 1 -C 3 alkyl, cyclopropyl, optionally substituted C 1 -C 3 alkoxy, cyano, hydroxyl, nitro or NH 2 ;

R 2 is H or F; and

R 3 is H, halogen, optionally substituted C 1 -C 3 alkyl, optionally substituted C 1 -C 3 alkoxy or cyano.

4. The compound according to claim 1 which is a compound of formula 5:

or a salt thereof, wherein

R 1 is halogen, optionally substituted C 1 -C 3 alkyl, cyclopropyl, optionally substituted C 1 -C 3 alkoxy, cyano, hydroxyl, nitro or NH 2 ;

R 2 is H or F;

R 5 is H, D, halogen, optionally substituted C 1 -C 3 alkyl or cyano; and

R 6 is H, D, halogen, optionally substituted C 1 -C 3 alkyl or cyano.

5. The compound according to claim 1 , wherein R 1 is F, Cl, OMe, CH 2 OMe, Me, fluoromethyl or cyano.

6. The compound according to claim 1 , wherein R 1 is F, Cl or cyano.

7. The compound according to claim 2 , wherein R 3 is H, Me, F, Cl or cyano.

8. The compound according to claim 2 , wherein n is 0 or 1.

9. The compound according to claim 4 , wherein R 5 and R 6 are independently H, D or F.

10. The compound according to claim 1 which is selected from the group consisting of:

3-chloro-4-fluoro-5-[6-(pyridin-2-yl)pyrimidin-4-yl]benzonitrile;

3-chloro-5-[6-(pyridin-2-yl)pyrimidin-4-yl]benzonitrile;

6-[6-(3-chloro-5-cyanophenyl)pyrimidin-4-yl]pyridine-3-carbonitrile;

3-methyl-5-[6-(pyridin-2-yl)pyrimidin-4-yl]benzonitrile;

3-methyl-5-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile;

3-chloro-5-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile;

3-chloro-4-fluoro-5-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile;

3-chloro-4-fluoro-5-[4-(1H-pyrazol-1-yl)pyridin-2-yl]benzonitrile;

3-chloro-4-fluoro-5-[2-(1H-pyrazol-1-yl)pyridin-4-yl]benzonitrile;

3-chloro-4-fluoro-5-[6-(4-fluoro-1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile;

3-methyl-5-{6-[( 2 H 3 )-1H-pyrazol-1-yl]pyrimidin-4-yl}benzonitrile;

3-chloro-5-{6-[( 2 H 3 )-1H-pyrazol-1-yl]pyrimidin-4-yl}benzonitrile;

3-chloro-4-fluoro-5-{6-[( 2 H 3 )-1H-pyrazol-1-yl]pyrimidin-4-yl}benzonitrile;

3-(fluoromethyl)-5-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile;

3-chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile;

5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzene-1,3-dicarbonitrile;

3-chloro-5-[6-(5-methylpyridin-2-yl)pyrimidin-4-yl]benzonitrile;

3-chloro-5-[6-(5-chloropyridin-2-yl)pyrimidin-4-yl]benzonitrile;

5-[6-(pyridin-2-yl)pyrimidin-4-yl]benzene-1,3-dicarbonitrile;

3-chloro-4-fluoro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile;

3-methyl-5-[6-(5-methylpyridin-2-yl)pyrimidin-4-yl]benzonitrile;

3-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]-5-(methoxymethyl)benzonitrile; and

3-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]-5-methoxybenzonitrile;

or a salt thereof.

11. The compound according to claim 1 which is selected from the group consisting of:

3-methyl-5-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile;

3-chloro-5-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile;

3-chloro-4-fluoro-5-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile;

3-chloro-4-fluoro-5-[4-(1H-pyrazol-1-yl)pyridin-2-yl]benzonitrile;

3-chloro-4-fluoro-5-[2-(1H-pyrazol-1-yl)pyridin-4-yl]benzonitrile;

3-chloro-4-fluoro-5-[6-(4-fluoro-1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile;

3-methyl-5-{6-[( 2 H 3 )-1H-pyrazol-1-yl]pyrimidin-4-yl}benzonitrile;

3-chloro-5-{6-[( 2 H 3 )-1H-pyrazol-1-yl]pyrimidin-4-yl}benzonitrile;

3-chloro-4-fluoro-5-{6-[( 2 H 3 )-1H-pyrazol-1-yl]pyrimidin-4-yl}benzonitrile; and

3-(fluoromethyl)-5-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile;

or a salt thereof.

12. A pharmaceutical composition comprising a compound according to claim 1 .

Assignments (3)
CHANGE OF NAME Recorded Aug 8, 2024
From: HEPTARES THERAPEUTICS LIMITED
To: NXERA PHARMA UK LIMITED
Reel/Frame 068230/0394 →
CHANGE OF ADDRESS Recorded Jun 1, 2022
From: HEPTARES THERAPEUTICS LIMITED
To: HEPTARES THERAPEUTICS LIMITED
Reel/Frame 060249/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2020
From: CHRISTOPHER, JOHN ANDREW; CONGREVE, MILES STUART; AVES, SARAH JOANNE; TEHAN, BENJAMIN GERALD
To: HEPTARES THERAPEUTICS LIMITED
Reel/Frame 052526/0519 →
Priority Claims (1)
GB 1312800.4 · Jul 17, 2013 · national
Continuity (4)
Continuation 16280512 · Feb 20, 2019
Continuation 15618504 · Jun 9, 2017
Continuation 14904907
Related Publication 20200172505A1 · Jun 4, 2020
Cited By (1)
US 12,415,795